skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Sponsors

IQVIA
New_Acceltra_R
Aurobindo
IHP
Pirimal Solutions
Pharmacloud
Pharmawiselogo

Global Generics & Biosimilars Awards 2019

Award Categories & Entry Criteria
 
These Awards took place on 5th November at the Frankfurt Marriott Hotel in Frankfurt, Germany.

Company of the Year
Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics or biosimilars.


Company of the Year, Americas

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.


Company of the Year, Asia-Pacific

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.


Company of the Year, EMEA

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.


Acquisition of the Year
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.


Leader of the Year

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.


Value Added Medicine Initiative of the Year - NEW
Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.


Business Development of the Year
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.


API Supplier of the Year

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.

Biosimilar Initiative of the Year
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.

Regulatory Achievement of the Year
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.

Legal Strategy of the Year
This category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; or ways in which legal strategies from different global jurisdictions have been used as a template elsewhere, showing the benefits of a co-ordinated international legal strategy.

 

Industry Partner of the Year
Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.

 

Corporate Social Responsibility (CSR) Initiative of the Year
Entries could include: company approach to CSR, implementation, engagement plans, training & education programmes, compulsory licensing and humanitarian aid donations.


Contact us today

For 2020 Sponsorship Opportunities contact:

Rob Coulson
Email: rob.coulson@informa.com
Tel: +44 (0) 7900 658185

For all other enquiries:
Natalie Cornwell
Email: natalie.cornwell@informa.com
Tel: +44 (0) 7827 993 776